<DOC>
	<DOCNO>NCT02174445</DOCNO>
	<brief_summary>This open-label , multicenter , randomise phase 3b clinical trial Imatinib 400 800 mg daily versus Nilotinib 300 mg two time daily chronic phase CML patient confirm MMR without MR4.5</brief_summary>
	<brief_title>An Open-label , Randomised Multicenter Phase 3b Study Determine Confirmed Rate Molecular Response ≥ 4 Log ( MR4 ) Two Years</brief_title>
	<detailed_description>This open-label , multicenter , randomise phase 3b clinical trial Imatinib 400 800 mg daily versus Nilotinib 300 mg two time daily chronic phase CML patient confirm MMR without MR4.5 ( receive Imatinib 400 800 mg daily least 18 month ) determine proportion patient confirm MR4 two year . Patients treatment arm A ( Imatinib ) achieve confirm MR4 2 year randomisation offer cross-over Imatinib 400 800 mg daily Nilotinib 300 mg twice daily . One hundred thirty-two ( 132 ) patient include randomised 1:1 treatment arm . The study stratify duration Imatinib treatment screen-ing ( ≤36 month / &gt; 36 month ) well level response inclusion ( MMR / MR4 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed write informed consent 2 . Male female patient age &gt; =18 year ( without upper limit age ) 3 . ECOG performance status 0 2 4 . CML chronic phase , chronic phase define blast &lt; 15 % blood and/or bone marrow peripheral blood basophil &lt; 20 % platelet ≥ 100 G/L 5 . Pretreatment Imatinib treatment duration least 18 month dosage 400 800 mg daily 6 . Major molecular response ( MMR ) without molecular response ≥ 4.5 log ( MR4.5 ) , i.e . BCRABL &gt; 0.0032 % ≤0.1 % IS confirmed central laboratory screening require randomisation 7 . Patients must serum Creatinine ≤ 1.5 x ULN , SGOT ≤ 1.5 x ULN , total bilirubin ≤ 1.5 x ULN ( except know M. Gilbert ) , Lipase ≤ 1.5 x ULN 8 . Women childbearing potential define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month , must negative serum pregnancy test screening period . Male female patient reproductive potential must agree employ highly effective method birth control throughout study 3 month follow discontinuation study drug . Appropriate method e.g . highly effective method first choice , i.e . method low failure rate ( le 1 % per year ) like sexual abstinence , combine oral contraceptive , implant , injectable , Intra Uterine Devices ( IUDs ) , vasectomized partner , combination method second choice like condom , diaphragm , cup pessary spermicidal foam/gel/film/cream/suppository . 1 . Any previous treatment CML Hydroxyurea , Imatinib Interferon alpha 2 . Evidence feature accelerate blast phase time 3 . Previous loss hematologic cytogenetic response 4 . Concomitant medication know strong inducer inhibitor P450 Isoenzyme CYP3A4 5 . Finding secondary BCRABL resistance mutation time 6 . History intolerance Imatinib require treatment interruption longer 4 week ( cumulative ) dose reduction less 400 mg daily longer 4 week ( cumulative ) last 12 month inform consent 7 . Patients prior allogeneic , syngeneic , autologous bone marrow transplant stem cell transplant 8 . Patients unwilling unable comply plan therapeutic intervention comply study treatment visit include blood sample collection within protocol 9 . History pancreatitis , chronic inflammatory disease autoimmune diseases 10 . Patients underwent solid organ transplantation 11 . Impaired cardiac function , include follow : History presence complete leave bundle branch block , right bundle branch block plus leave anterior hemi block , bifascicular block screen ECG Use cardiac pacemaker ST depression &gt; 1mm 2 lead and/or T wave inversion 2 contiguous lead screen ECG Congenital Long QT Syndrome QTc &gt; 450 msec screen ECG QT prolong concomitant medication History presence significant ventricular atrial tachyarrhythmia screen ECG History presence clinically significant rest bradycardia ( &lt; 50 beat per minute ) Myocardial infarction within 12 month prior inform consent Unstable angina diagnose treat past 12 month inform consent Other clinically significant heart disease ( e.g. , congestive heart failure , uncontrolled hypertension , history labile hypertension ) 12 . Known HIV and/or hepatitis B C infection ( test mandatory ) 13 . Other malignancy within past 3 year informed consent except adequately treat carcinoma cervix basal squamous cell carcinoma skin 14 . Women pregnant breast feed 15 . Male/female patient reproductive potential unwilling practice highly effective method birth control 16 . History noncompliance medical regimen 17 . Treatment another investigational product study last 30 day prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Patients CML chronic phase</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Nilotinib</keyword>
</DOC>